Vitura Health (ASX:VIT) ROC (Joel Greenblatt) %: -1.89% (As of Dec. 2025)


What is Vitura Health ROC (Joel Greenblatt) %?

Vitura Health ASX:VIT ROC (Joel Greenblatt) % is -1.89% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 978 Drug Manufacturers companies, Vitura Health ranks better than 73.21% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Vitura Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1.89%.

The historical rank and industry rank for Vitura Health's ROC (Joel Greenblatt) % or its related term are showing as below:

ASX:VIT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -804.46   Med: 84.6   Max: 278.49
Current: 28.77

During the past 7 years, Vitura Health's highest ROC (Joel Greenblatt) % was 278.49%. The lowest was -804.46%. And the median was 84.60%.

ASX:VIT's ROC (Joel Greenblatt) % is ranked better than
73.21% of 978 companies
in the Drug Manufacturers industry
Industry Median: 11.45 vs ASX:VIT: 28.77

Vitura Health's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Vitura Health  (ASX:VIT) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Vitura Health ROC (Joel Greenblatt) % Related Terms


Vitura Health ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Vitura Health's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitura Health ROC (Joel Greenblatt) % Chart

Vitura Health Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -295.92 276.64 278.49 72.66 96.54

Vitura Health Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 125.71 19.61 64.89 58.06 -1.89

ASX:VIT vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitura Health ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vitura Health's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Vitura Health's ROC (Joel Greenblatt) % falls into.



Vitura Health ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.004 + 5.978 + 1.63) - (13.347 + 1.487 + 0.883)
=1.895

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.879 + 6.889 + 1.252) - (13.655 + 0 + 1.987)
=5.378

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Vitura Health for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.126/( ( (3.159 + max(1.895, 0)) + (2.87 + max(5.378, 0)) )/ 2 )
=-0.126/( ( 5.054 + 8.248 )/ 2 )
=-0.126/6.651
=-1.89 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -1.89% mean?
Vitura Health (ASX:VIT) has a ROC (Joel Greenblatt) % of -1.89% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vitura Health and its competitors. According to the industry distribution chart, Vitura Health ranks #262 out of 978 companies in the Drug Manufacturers industry, placing it in the top 26.8%.
Is Vitura Health's ROC (Joel Greenblatt) % too high?
Vitura Health's current ROC (Joel Greenblatt) % is -1.89%. Based on the distribution chart, Vitura Health ranks #262 out of 978 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Vitura Health's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #262 out of 978 companies for ROC (Joel Greenblatt) %. This puts Vitura Health in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Vitura Health and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current ROC (Joel Greenblatt) % is -1.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 73% below its estimated fair value. The current ROC (Joel Greenblatt) % is -1.89%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current ROC (Joel Greenblatt) % is -1.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitura Health Business Description

Address 299 Toorak Road, Suite 8, Level 3, South Yarra, VIC, AUS, 3141
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.